Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rxolve Ultra is a topical ophthalmic eye drop developed by Rxilient Health for the treatment of moderate-to-severe dry eye syndrome and corneal ablations. The formulation contains 0.3% high molecular weight hyaluronic acid (sodium hyaluronate), which functions as a lubricant and humectant to provide long-lasting hydration and reduce inflammation of the ocular surface. It is a preservative-free solution packaged in a patented 10ml multi-dose bottle designed to maintain sterility for up to one year after opening. The product is suitable for use by adults, children, and contact lens wearers, providing relief from symptoms such as dryness, irritation, redness, and itchiness associated with dry eye syndrome.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Rxolve Ultra.